From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
CPT code | Explanation | Multiplier | NLA | Total NLA |
---|---|---|---|---|
83891 | DNA Isolation | 1 | $5.7 | $5.7 |
83900 | Amplification of patient nucleic acid, multiplex, first two nucleic sequences | 1 | $47.8 | $47.8 |
83901 | Amplification of patient nucleic acid, multiplex, each additional acid sequence | 10 | $23.7 | $237 |
83892 | Digestion of amplified DNA with restriction endonuclease enzyme, each | 2 | $5.7 | $11.4 |
83914 | Mutation identification by enzymatic ligation or primer extension, single segment, each segment [e.g. oligonucleotide ligation assay (OLA), single base chain extension (SBCE), or allele-specific primer extension (ASPE)] | 15 | $23.7 | $356 |
83912 | Interpretation and report | 1 | $5.7 | $5.7 |
83896 | Nucleic acid probe, each | 15 | $5.7 | $85 |
83903 | Molecular diagnostics; mutation scanning by physical properties, single segment, each | 15 | $23.7 | $356 |
83908 | Molecular diagnostics; signal amplification of patient nucleic acid, each nucleic acid sequence | 15 | $23.7 | $356 |
Cost per patient tested | $1461 | |||
Adjusted for a genetic testing age of 65Â years and ranibizumab. Total treatment age of 75Â years (compounded at 3Â % annually) | $1906 | |||
Including the $299 incremental yearly ophthalmic examination and optical coherence. Total tomogram in the 20Â % of patients with a high-risk genetic score [4] | $2205 |